Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | BRS3 | P32247 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | LATS1 | O95835 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29950993 | 1.00 | NAMPT (0.46) | NAMPTCYP17A1RAB9AMETAP1BRS3 | |
| SCHEMBL29955026 | 0.88 | NAMPT (0.46) | NAMPTCYP17A1RAB9AMETAP1BRS3 | |
| SCHEMBL1233798 | 0.88 | NAMPT (0.46) | NAMPTCYP17A1RAB9AMETAP1BRS3 | |
| SCHEMBL18522430 | 0.84 | NAMPT (0.50) | NAMPTCYP17A1RAB9AMETAP1BRS3 | |
| SCHEMBL3666785 | 0.82 | NAMPT (0.48) | NAMPTCYP17A1RAB9AMETAP1BRS3 | |
| SCHEMBL2107971 | 0.82 | NAMPT (0.48) | NAMPTCYP17A1RAB9AMETAP1BRS3 | |
| SCHEMBL18832828 | 0.82 | NAMPT (0.43) | NAMPTCYP17A1RAB9AMETAP1BRS3 | |
| SCHEMBL29957527 | 0.81 | CYP17A1 (0.47) | NAMPTCYP17A1RAB9AMETAP1BRS3 | |
| SCHEMBL1197794 | 0.81 | CYP17A1 (0.47) | NAMPTCYP17A1RAB9AMETAP1BRS3 | |
| SCHEMBL536056 | 0.81 | NOD2 (0.50) | NAMPTCYP17A1RAB9AMETAP1ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2850044-B1 | USE OF FLUORINATED DERIVATIVES OF 4-AMINOPYRIDINE IN THERAPEUTICS AND MEDICAL IMAGING | UNIV CHICAGO (US) | 2017-05-17 | — | — | EP | claimed |
| EP-2850044-A2 | USE OF FLUORINATED DERIVATIVES OF 4-AMINOPYRIDINE IN THERAPEUTICS AND MEDICAL IMAGING | The University of Chicago (US) | 2015-03-25 | — | — | EP | claimed |
| WO-2013173746-A2 | USE OF FLUORINATED DERIVATIVES OF 4-AMINOPYRIDINE IN THERAPEUTICS AND MEDICAL IMAGING | THE UNIVERSITY OF CHICAGO (US) | 2013-11-21 | — | — | WO | claimed |
| CN-107922394-B | 3-tetrazolyl-benzene-1, 2-disulfonamide derivatives as metallo-beta-lactamase inhibitors | 默沙东公司 | 2021-07-13 | — | — | CN | disclosed |
| EP-3313832-B1 | 3-TETRAZOLYL-BENZENE-1,2-DISULFONAMIDE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME (US) | 2021-02-24 | — | — | EP | disclosed |
| US-20210017133-A1 | USE OF FLUORINATED DERIVATIVES OF 4-AMINOPYRIDINE IN THERAPEUTICS AND MEDICAL IMAGING | THE UNIVERSITY OF CHICAGO | 2021-01-21 | — | — | US | disclosed |
| US-10544130-B2 | Metallo-beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-01-28 | — | — | US | disclosed |
| US-10442767-B2 | Use of fluorinated derivatives of 4-aminopyridine in therapeutics and medical imaging | THE UNIVERSITY OF CHICAGO (US) | 2019-10-15 | — | — | US | disclosed |
| US-20190144432-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-05-16 | — | — | US | disclosed |
| US-10221163-B2 | Metallo-beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20180244656-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-08-30 | — | — | US | disclosed |
| US-20090075980-A1 | Pyrazolopyridines and Analogs Thereof | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-03-19 | — | — | US | disclosed |
| WO-2007143526-A2 | SUBSTITUTED TETRAHYDROIMIDAZONAPHTHYRIDINES AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2007-12-13 | — | — | WO | disclosed |
| EP-1863809-A2 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | Coley Pharmaceutical Group, Inc. (US) | 2007-12-12 | — | — | EP | disclosed |
| EP-1863770-A2 | RING CLOSING AND RELATED METHODS AND INTERMEDIATES | Coley Pharmaceutical Group, Inc. (US) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006121528-A2 | RING CLOSING AND RELATED METHODS AND INTERMEDIATES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006107753-A2 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-10-12 | — | — | WO | disclosed |
| EP-1696912-A2 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | 3M Innovative Properties Company (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20060100229-A1 | Pyrazolopyridines and analogs thereof | 3M INNOVATIVE PROPERTIES COMPANY | 2006-05-11 | — | — | US | disclosed |
| WO-2005079195-A2 | PYRAZOLOPYRIDINES AND ANALOGS THEREOF | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017133-A1 | USE OF FLUORINATED DERIVATIVES OF 4-AMINOPYRIDINE IN THERAPEUTICS AND MEDICAL IMAGING | KCNQ4, KCNJ4, KCNQ2 | NAMPT 3975/4885CYP17A1 4714/4885RAB9A 1390/4885 |
| US-10544130-B2 | Metallo-beta-lactamase inhibitors | MLX, ZFX, MMP12 | NAMPT 2330/4885CYP17A1 193/4885RAB9A 438/4885 |
| US-20090075980-A1 | Pyrazolopyridines and Analogs Thereof | IL4, IL4I1, IL2 | NAMPT 121/4885CYP17A1 4407/4885RAB9A 2019/4885 |
| US-20060100229-A1 | Pyrazolopyridines and analogs thereof | IL4, IL2, IL4I1 | NAMPT 329/4885CYP17A1 4645/4885RAB9A 1946/4885 |
| US-10221163-B2 | Metallo-beta-lactamase inhibitors | MLX, ZFX, MMP12 | NAMPT 2351/4885CYP17A1 184/4885RAB9A 474/4885 |
| US-20190144432-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MLX, ZFX, MMP12 | NAMPT 2330/4885CYP17A1 193/4885RAB9A 438/4885 |
| US-10442767-B2 | Use of fluorinated derivatives of 4-aminopyridine in therapeutics and medical imaging | KCNJ4, KCNQ4, KCNQ2 | NAMPT 3874/4885CYP17A1 4883/4885RAB9A 1331/4885 |
| US-20180244656-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MLX, ZFX, MMP12 | NAMPT 2351/4885CYP17A1 184/4885RAB9A 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.